Targets › HLA-A2
1 program from 1 company in 1 trial: 1 Phase 1; Gastroenterology; next expected readout Sep 2040.
Open in Phaseline: the race on HLA-A2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Quell Therapeutics | QEL-001 CAR-Treg (chimeric antigen receptor-engineered regulatory T cell) targeting HLA-A2 | HLA-A2 | Phase 1 | Rejection; Transplant, Liver | Sep 2040 |
Rejection; Transplant, Liver (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.